Last $303.55 USD
Change Today +4.45 / 1.49%
Volume 1.8M
BIIB On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Frankfurt
As of 8:10 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

225 Binney Street

Cambridge, MA 02142

United States

Phone: 781-464-2000

Fax:

ences, Inc. focused on the development of therapeutics for hemoglobinopathies, inherited conditions that result from the abnormal structure or underproduction of hemoglobin. In 2013, the company entered into a collaborative research, development, commercialization and license agreement with Proteostasis Therapeutics, Inc. under which both companies would develop and commercialize small molecule therapeutics for the treatment of neurological diseases. In September 2013, the company entered into a six-year research collaboration with Isis Pharmaceuticals, Inc. under which both companies would perform discovery level research and develop and commercialize antisense and other therapeutics for the treatment of neurological disorders. In 2013, the company entered into a Platform Agreement with Adimab LLC (Adimab). Pursuant to the agreement, Adimab granted it a non-exclusive license to its proprietary antibody discovery platform that enables its researchers to utilize the Adimab technology for the discovery and optimization of all antibody formats, including bispecific antibodies. Trademarks The company’s trademarks, including AVONEX, RITUXAN, TECFIDERA and TYSABRI, are important to it and are generally covered by trademark applications or registrations in the USPTO and the patent or trademark offices of other countries. AVONEX and Pegylated Beta Interferon: The company has non-exclusive rights under certain third-party patents and patent applications to manufacture, use, and sell AVONEX, including a patent owned by the Japanese Foundation for Cancer Research, which expires in 2013 in the U.S. Additionally, the company and third parties own pending U.S. patent applications related to recombinant interferon-beta protein and nucleic acid. Additional protection for its pegylated beta interferon is provided by patents and patent applications with expiration dates in 2021 in the U.S. and 2019 in the E.U., with the potential for patent term extension. TYSABRI: The company has patent applications covering TYSABRI in the U.S. and other countries. These patents and patent applications cover TYSABRI and related manufacturing methods, as well as various methods of treatment using the product. In the U.S., the principal patents covering the product and use of the product to treat MS generally expire between 2015 and 2020. Additional U.S. patents and applications covering other indications, including treatment of inflammatory bowel disease, and methods of manufacturing, generally expire between 2012 and 2020. In the rest of world, patents on the product and methods of manufacturing the product generally expire between 2015 and 2020, subject to any supplemental protection (patent term extension) certificates that might be obtained. In the rest of world, patents and patent applications covering methods of treatment using TYSABRI generally expire between 2012 and 2020. TECFIDERA The company has various U.S. patents and patent applications, and various corresponding foreign counterparts, related to TECFIDERA. RITUXAN and Anti-CD20 Antibodies: The company has various U.S. patents and patent applications, and various corresponding foreign counterparts, directed to anti-CD20 antibody technology, including RITUXAN. The principal patents with claims to RITUXAN or its uses expire in the U.S. between 2015 and 2018 and in the rest of the world in 2013, subject to any available patent term extensions. In addition, the company and its collaborator, Genentech, have filed various patent applications directed to anti-CD20 antibodies and their uses to treat various diseases. Genentech, its collaborator on RITUXAN, has secured a license to five U.S. patents and counterpart U.S. and foreign patent applications assigned to Xoma Corporation that relate to chimeric antibodies against the CD20 antigen. These patents expire between 2007 and 2014. FAMPYRA: The company has a license under two European granted patents, various pending European patent applications, and various corresponding non-U.S. counterpart applications related to FAMPYRA. ELOCTATE [Antihemophilic Factor, Fc Fusion Protein (Recombinant)] and ALPROLIX [Coagulation

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIIB:US $303.55 USD +4.45

BIIB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,762 JPY -18.50
Celgene Corp $108.20 USD +0.85
Novo Nordisk A/S kr265.80 DKK +2.00
Shire PLC 4,474 GBp +5.00
Thermo Fisher Scientific Inc $126.54 USD +1.96
View Industry Companies
 

Industry Analysis

BIIB

Industry Average

Valuation BIIB Industry Range
Price/Earnings 28.7x
Price/Sales 7.9x
Price/Book 6.9x
Price/Cash Flow 24.3x
TEV/Sales 7.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOGEN IDEC INC, please visit www.biogenidec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.